CD4 cell response before and after HAART initiation according to viral load and growth indicators in HIV-1-infected children in abidjan, côte d'ivoire

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 1, 2008, Pages 70-76

  Beaudrap, Pierre De ^a,b,c,d,e   Rouet, François ^f   Fassinou, Patricia ^g   Kouakoussui, Alain ^h   Mercier, Sabine ⁱ   Ecochard, René ^a,b   Msellati, Philippe ^a,b  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b Centre de Recherche Cultures Santé Sociétés   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d UNIVERSITÉ LYON 1   (France)

^e LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE YOPOUGON   (Côte d’Ivoire)

^h Programme ANRS 1244 1278 Enfant Yopougon   (Côte d’Ivoire)

ⁱ CATIE   (Costa Rica)

Author keywords

AIDS; Developing country; Epidemiology; Immunology; Pediatric

Indexed keywords

COTRIMOXAZOLE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AGE DISTRIBUTION; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CD4 LYMPHOCYTE PERCENTAGE; CD4+ T LYMPHOCYTE; CHILD; CHILD GROWTH; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE; VIRUS LOAD; AGE; COTE D'IVOIRE; GROWTH; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PATHOPHYSIOLOGY;

AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY MASS INDEX; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; COTE D'IVOIRE; GROWTH; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; VIRAL LOAD;

EID: 52049122439     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181831847     Document Type: Article

References (42)

1. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352:1725-1730.
2. Kong F, Chen CH, Cooper MD. Thymic function can be accurately monitored by the level of recent T cell emigrants in the circulation. Immunity. 1998;8:97-104.
3. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528.
4. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;44:599-604.
5. Gibb DM, Newberry A, Klein N, et al. Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee. Lancet. 2000;355:1331-1332.
6. Sleasman JW, Nelson RP, Goodenow MM, et al. Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. J Pediatr. 1999;134: 597-606.
7. Resino S, Seoane E, Perez A, et al. Different profiles of immune reconstitution in children and adults with HIV-infection after highly active antiretroviral therapy. BMC Infect Dis. 2006;6:112.
8. Vigano A, Vella S, Saresella M, et al. Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS. 2000;14:251-261.
9. Battegay M, Nuesch R, Hirschel B, et al. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis. 2006;6: 280-287.
10. Le Moing V, Thiebaut R, Chene G, et al. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis. 2002;185:471-480.
11. Garcia F, de Lazzari E, Plana M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr. 2004;36:702-713.
12. Tarwater PM, Margolick JB, Jin J, et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:168-175.
13. Anselmi A, Vendrame D, Rampon O, et al. Immune reconstitution in human immunodeficiency virus type 1-infected children with different virological responses to anti-retroviral therapy. Clin Exp Immunol. 2007; 150:442-450.
14. van Rossum AM, Scherpbier HJ, van Lochem EG, et al. Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status. AIDS. 2001;15:2267-2275.
15. Resino S, Correa R, Bellon JM, et al. Characterizing immune reconstitution after long-term highly active antiretroviral therapy in pediatric AIDS. AIDS Res Hum Retroviruses. 2002;18:1395-1406.
16. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS. 2003;17:1907-1915.
17. Verweel G, van Rossum AM, Hartwig NG, et al. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics. 2002;109:E25.
18. Committee on Pediatric AIDS. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS. 2006;20:1289-1294.
19. Eley B, Nuttall J. Antiretroviral therapy for children: challenges and opportunities. Ann Trop Paediatr. 2007;27:1-10.
20. Dunn D, Woodburn P, Duong T, et al. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis. 2008;197:398-404.
21. Dunn D, and the HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a metaanalysis. Lancet. 2003;362:1605-1611.
22. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire. AIDS. 2004; 18: 1905-1913.
23. Rouet F, Fassinou P, Inwoley A, et al. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS. 2006;20:2315-2319.
24. World Health Organization. Antiretroviral Therapy of HIV Infection in Infants and Children in Resource-Limited Settings: Towards Universal Access. Recommendations for a Public Health Approach. Geneva, Switzerland: WHO; 2006: 171.
25. Rouet F, Ekouevi DK, Chaix ML, et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol. 2005; 43:2709-2717.
26. Diggle P, Liang K, Zeger S. Analysis of Longitudinal Data. Oxford, United Kingdom: Clarendeon Press; 1994.
27. Pinheiro J, Bates D. Mixed-Effects Models in Sand S-Plus. New York, NY: Springer; 2000.
28. Naumova E, Must A, Laird N. Tutorial in biostatistics: evaluating the impact of 'critical periods' in longitudinal studies of growth using piecewise mixed effects models, bit J Epidemiol. 2001;30:1332-1341.
29. Potvin C, Lechowicz MJ, Tardif S. The statistical analysis of ecophysiological response curves obtained from experiments involving repeated measures. Ecology. 1990;71:1389-1400.
30. R Development Core Team. R: A Language and Environment for Statistical Computing. R: Vienna, Austria: R Foundation for Statistical Computing; 2006.
31. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298:1888-1899.
32. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. Pediatr Infect Dis J. 2007;26:953-956.
33. Patel K, Hernán MA, Williams PL, et al. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis. 2008;46:1751-1760.
34. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20:1181-1189.
35. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
36. Lawn SD, Myer L, Orrell C, et al. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005;19:2141-2148.
37. Resino S, Correa R, Bellon JM, et al. Preserved immune system in longterm asymptomatic vertically HIV-1 infected children. Clin Exp Immunol. 2003;132:105-112.
38. Johnston AM, Valentine ME, Ottinger J, et al. Immune reconstitution in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy: a cohort study. Pediatr Infect Dis J. 2001;20: 941-946.
39. van Rossum AM, de Groot R. Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J. 2003;22:934. Author reply 934-935.
40. Clerici M, Saresella M, Trabattoni D, et al. Thymic volume predicts longterm immune reconstitution in HIV-infected children treated with highly active antiretroviral therapy. AIDS. 2002;16:2219-2221.
41. Violari A, Cotton M, Gibb D, et al, on behalf of the CHER Study Team. Antiretroviral Therapy Initiated Before 12 weeks of Age Reduces Early Mortality in Young HIV-infected Infants: Evidence From the Children With HIV Early Antiretroviral Therapy (CHER) Study. Special Session: Proceedings of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention: Sydney, Australia. July 22-25, 2007. Abstract WESS103. Available at http://www.ias2007.org/pag/PSession.aspx?s=150.
42. Kovacs A, Montepiedra G, Carey V, et al. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. J Infect Dis. 2005;192:296-302.